Publication Of Cytori Breast Reconstruction Cell Therapy Trial Results
 

Cytori Therapeutics (NASDAQ: CYTX) has announced the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology. RESTORE-2 is a 71 patient multi-center, prospective clinical trial using autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for reconstruction of the breast after cancer surgery...

More...